Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis

NIAID Data Ecosystem2026-03-14 收录

结直肠癌肝转移治疗

联合疗法评估

数据链接：

https://www.omicsdi.org/dataset/ecrin-mdr-crc/2747042 数据链接链接失效反馈

官方服务：

资源简介：

To evaluate the safety and efficacy of sintilimab combined with regorafenib and HAIC in patients with colorectal liver metastasis who failed second-line therapy

创建时间：

2022-09-15

Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver

结直肠癌肝转移治疗

肝动脉灌注化疗

Background: Many people with colorectal cancer get liver metastases. Standard treatment for this is a combination of chemotherapy drugs. Directing the chemotherapy to the liver may be effective. A dev

NIAID Data Ecosystem60

Chemotherapy Alone Versus Chemotherapy Plus Targeted Therapy as Adjuvant Therapy for Initially Unresectable Colorectal Cancer Liver Metastases

结直肠癌肝转移治疗

靶向治疗疗效

Chemotharapy plus targeted therapy regimen, as an adjuvant therapy, can effectively reduce the rate of both intrahepatic and extrahepatic recurrence in initially unresectable CRLM patients. Those with

NIAID Data Ecosystem50

Additivity predicts the efficacy of most approved combination therapies for advanced cancer

联合疗法评估

药物协同预测

This contains data related to the publication "Additivity predicts the efficacy of most approved combination therapies for advanced cancer". Input sheets: placebo_input_sheet.txtapproved_combination_t

NIAID Data Ecosystem30

The application and exploration of Fruquintnib combined with TAS-102 and Stereotactic Body Radiotherapy(SBRT)for Third-line and Beyond Treatment of Metastatic Colorectal Cancer

转移性结直肠癌治疗

联合疗法评估

Interventions: Cohort 1:Fruquintnib combined with TAS-102 and SBRT;Cohort 2:Fruquintnib combined with TAS-102 Primary outcome(s): Progression-free survival assessed by the investigator Study Design: F

NIAID Data Ecosystem50

Intra-arterial hepatic beads loaded with irinotecan (Debiri) with concomitant chemotherapy with FOLFOX in patients with colorectal cancer with unresectable liver metastases: a phase II multicenter study

结直肠癌肝转移治疗

生存率评估

Primary objectives: Taux de survie sans progression à 9 mois selon RECIST 1.1. Primary endpoints: Le critère de jugement principal sera d’évaluer la proportion de patients vivants sans progression (le

NIAID Data Ecosystem40

Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis

资源简介：

相关数据集